Macular degeneration
Drug Safety Update
January 2022: Brolucizumab (Beovu▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals
July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
April 2016: Aflibercept (Zaltrap▼): minimising the risk of osteonecrosis of the jaw
NICE Guidance (see also drug specific links below)
NG82: Age-related macular degeneration, January 2018.
NG1022: Bevacizumab gamma for treating wet age-related macular degeneration, December 2024.
These drugs are for specialist use only and should be used in accordance with NICE guidance.
| Pack |
|---|
| 1 pre-filled disposable injection |
| Pack |
|---|
| 1 vial |
| Pack |
|---|
| 1 vial |
| Pack |
|---|
| 1 vial |
| Pack |
|---|
| 1 pre-filled disposable injection |
| Pack |
|---|
| 1 pre-filled disposable injection |
| Pack |
|---|
| 1 vial |
- On Formulary Preferred
- On Formulary Second Line
- On Formulary Third Line
- Specialist Initiation
- Secondary Care Only
- Not Approved for Formulary